Hepatitis D future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Joao Silva (talk | contribs) No edit summary |
Joao Silva (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
Although the lack of viral enzymes represents a challenge in the development of antiviral drugs, the life cycle of HDV relies deeply on postranslational modification and viral assembly. Therefore, these two steps are potential targets of antiviral drugs. | |||
==References== | ==References== | ||
Revision as of 11:32, 11 August 2014
|
Hepatitis D |
|
Diagnosis |
|
Treatment |
|
Hepatitis D future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Hepatitis D future or investigational therapies |
|
Risk calculators and risk factors for Hepatitis D future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2] Jolanta Marszalek, M.D. [3]
Overview
Future or Investigational Therapies
Although the lack of viral enzymes represents a challenge in the development of antiviral drugs, the life cycle of HDV relies deeply on postranslational modification and viral assembly. Therefore, these two steps are potential targets of antiviral drugs.